Author:
Abdulhamid Ibrahim,Guglani Lokesh,Bouren Jennifer,Moltz Kathleen C
Abstract
Purpose
– Annual screening for cystic fibrosis-related-diabetes (CFRD) using oral glucose tolerance test (OGTT) is recommended, but national testing rates are low. The purpose of this paper is to implement the quality improvement (QI) initiative to improve cystic fibrosis (CF) annual screening rates among patients at one CF center.
Design/methodology/approach
– To improve screening for CFRD at the CF Center, the authors used the Dartmouth Microsystem Improvement Ramp method and formed a collaborative working group. A process map was created to outline the steps and a fishbone analysis was performed to identify barriers and to utilize resources for implementing new interventions.
Findings
– Prior to these interventions, 21 percent of eligible patients had completed annual screening and after the intervention, it rose to 72 percent. The initial completion rate with the first prescription was only 50 percent, but it improved steadily to 54/75 (72 percent) in response to reminder letters sent six weeks after the initial script was given.
Practical implications
– Close tracking and reminder letters can improve adherence with annual OGTT screening for CFRD among CF patients, with special emphasis on high-risk patients.
Originality/value
– There should be a special emphasis on screening for CFRD in high-risk CF patients (those with low BMI or higher age). This QI initiative brought about several operational changes in the annual OGTT screening process that have now become the standard operating procedure at the center.
Subject
Health Policy,General Business, Management and Accounting
Reference11 articles.
1. Cystic Fibrosis Foundation
(2013), “Cystic fibrosis foundation patient registry 2012 annual data report”, Cystic Fibrosis Foundation, Bethesda, MD.
2. Godfrey, M.M.
,
Nelson, E.C.
,
Wasson, J.H.
,
Mohr, J.J.
and
Batalden, P.B.
(2003), “Microsystems in health care: part 3. Planning patient-centered services”,
Joint Communications Journal of Quality and Safety
, Vol. 29 No. 4, pp. 159-170.
3. Kern, A.S.
and
Prestridge, A.L.
(2013), “Improving screening for cystic fibrosis-related diabetes at a pediatric cystic fibrosis program”,
Pediatrics
, Vol. 132 No. 2, pp. e512-518.
4. Marshall, B.C.
,
Butler, S.M.
,
Stoddard, M.
,
Moran, A.M.
,
Liou, T.G.
and
Morgan, W.J.
(2005), “Epidemiology of cystic fibrosis-related diabetes”,
Journal of Pediatrics
, Vol. 146 No. 5, pp. 681-687.
5. Milla, C.E.
,
Warwick, W.J.
and
Moran, A.
(2000), “Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline”,
American Journal of Respiratory and Critical Care Medicine
, Vol. 162 No. 3, Part 1, pp. 891-895.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献